ClinicalTrials.gg
CompletedNCT00144209Updated Nov 1, 2013

Assess Efficacy and Safety of the Dopamine Agonist Pramipexole Versus Levodopa / Benserazide (Madopar® DR) in Patients With Restless Legs Syndrome

A Phase 3 interventional study of pramipexole and levodopa in combination with benserazide in Restless Legs Syndrome, sponsored by Boehringer Ingelheim. Completed at 6 sites in Switzerland. Open to participants aged 25 Years to 85 Years. Per ClinicalTrials.gov, last updated 2013-11-01.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
58
Allocation
Randomized
Ages
25 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing pramipexole in Restless Legs Syndrome — none open to participants now, 1 under way, none of them phase 3. Pramipexole · Restless Legs Syndrome.

Enrollment
12th of 17
58 · median 154
Started
2003
the only one that year
Phase 3
6 of 17
none open now
Registered
2nd of 17
by date
Lead sponsor
12 of 17
Boehringer Ingelheim

Among the 17 studies testing pramipexole in Restless Legs Syndrome, this one is the 12th largest by enrollment, is the only one that started in 2003, is one of 6 in phase 3, and was the 2nd registered.

Restless Legs Syndrome

259 studies on the registry are indexed under Restless Legs Syndrome; 38 are open to participants now.

Browse Restless Legs Syndrome studies →

Open to participants now

None of the 17 studies testing pramipexole in Restless Legs Syndrome is open now. The open studies under Restless Legs Syndrome, anywhere →

About pramipexole

Pramipexole: first FDA approval 1997 (MIRAPEX), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 25 Restless Legs Syndrome studies recruiting now, 10 (40%) set no upper age limit and 12 (48%) stop at 75 or younger; none take children under 18; 10 take healthy volunteers.

This study: 25 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 17 studies testing pramipexole in Restless Legs Syndrome as a file.
02

Study summary

The primary objective of this study is to determine that pramipexole (Sifrol) 0.25 mg to 0.75 mg daily is not inferior to levodopa 100 mg to 300 mg (in combination with benserazide 25mg to 75mg = Madopar DR) daily in the treatment of patients with idiopathic restless legs syndrome fulfilling the International Diagnostic Criteria. The efficacy parameters include an objective measure of the leg movements during the time spent in bed, and a quantitative clinical assessment of the severity of RLS, in the form of the RLS-score. In addition, the efficacy evaluations aim at comparing the impact of pramipexole and levodopa on outcome measures such as quality of life and sleep.

03

Conditions studied

  • Restless Legs Syndrome
04

Who can participate

Ages eligible
25 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients diagnosed with idiopathic restless legs syndrome fulfilling the International Diagnostic Criteria 1 .
  • Male or female patients, aged 25 to 85 years.
  • Patients presenting RLS symptoms almost every day, as judged by the investigator and with more than 5 PLM/h during bedtime in each of three screening actigraphy nights.
  • Patients must have given written in accordance with ICH-GCP and local legislation prior to participation in the study.

Exclusion criteria

Exclusion criteria:

  • Patients with significant diseases other than restless legs syndrome will be excluded. A significant disease is defined as a disease that, which in the opinion of the investigator may put the patient at a risk because of the participation in the study, that may influence the result of the study or the patient's ability to participate or that is expected to relevantly reduce .
  • Patients with known or to pramipexole, levodopa or benserazide or any other substances present in the study medications.
  • Patients with iron-deficiency
  • Patients with disabilities or other incapacities that preclude regular attendance at clinic for the study visits, and patients on a shift-work-schedule or who are otherwise unable to follow a regular sleep-wake cycle.
  • Patients who have been previously treated with pramipexole or levodopa.
  • Pregnant or nursing women or women of childbearing age who are at risk of pregnancy and are not willing to use adequate methods (hormonal contraception or intrauterine devices) during the study period.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double
Enrollment
58 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Frequency of periodic limb movements while in bed (PLM-I)

    Time frame: after 4 weeks

Secondary outcomes

  1. Changes in RLS-score

    Time frame: after 4 weeks

  2. Changes in sleep quality as assessed in a sleep diary

    Time frame: after 4 weeks

  3. Changes in Quality of Life (SF-36)

    Time frame: after 4 weeks

  4. Mood changes measured by Hospital Anxiety and Depression Scale (HAD)

    Time frame: after 4 weeks

  5. Overall impression assessed by Clinical Global Impression (CGI)

    Time frame: after 4 weeks

  6. Changes in daytime sleepiness as assessed by the Epworth Sleepiness Scale (ESS)

    Time frame: after 4 weeks

  7. Incidence and Intensity of Adverse events

    Time frame: up to 10 weeks

  8. Changes in safety laboratory values

    Time frame: up to 10 weeks

07

Study locations

6 sites
  • Boehringer Ingelheim Investigational Site
    Basel, 4025, Switzerland
  • Boehringer Ingelheim Investigational Site
    Basel, 4031, Switzerland
  • Boehringer Ingelheim Investigational Site
    Bern, 3000, Switzerland
  • Boehringer Ingelheim Investigational Site
    Lugano, CH-6900, Switzerland
  • Boehringer Ingelheim Investigational Site
    Zurich, 8091, Switzerland
  • Boehringer Ingelheim Investigational Site
    Zurzach, 5330, Switzerland
08

References and documents

Publications

  • Bassetti CL, Bornatico F, Fuhr P, Schwander J, Kallweit U, Mathis J; Swiss RLS study group. Pramipexole versus dual release levodopa in restless legs syndrome: a double blind, randomised, cross-over trial. Swiss Med Wkly. 2011 Nov 21;141:w13274. doi: 10.4414/smw.2011.13274. eCollection 2011. PubMed 22101745 ↗
  • Kallweit U, Khatami R, Pizza F, Mathis J, Bassetti CL. Dopaminergic treatment in idiopathic restless legs syndrome: effects on subjective sleepiness. Clin Neuropharmacol. 2010 Nov-Dec;33(6):276-8. doi: 10.1097/WNF.0b013e3181fd82a1. PubMed 21060282 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2003, a primary completion of Feb 2005 and a completion of Feb 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 2, 2005
First posted
Sep 5, 2005
Start
Feb 2003
Primary completionActual
Feb 2005
Completion
Feb 2005
Last update
Nov 1, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 1, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00144209
First posted
Sep 5, 2005
Start date
Feb 2003
Primary completion
Feb 2005
Completion
Feb 2005
Last update
Nov 1, 2013

Study contacts

Boehringer Ingelheim Study Coordinator
study chair · B.I. Schweiz GmbH.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pramipexole

Start the discussion